The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Oteracil     4,6-dioxo-1H-1,3,5-triazine- 2-carboxylic acid

Synonyms: Oxonate, Oteracil [INN], Oxonic Acid, CHEMBL181932, SureCN464773, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Oxonic Acid


High impact information on Oxonic Acid


Chemical compound and disease context of Oxonic Acid


Biological context of Oxonic Acid


Anatomical context of Oxonic Acid


Associations of Oxonic Acid with other chemical compounds


Gene context of Oxonic Acid


Analytical, diagnostic and therapeutic context of Oxonic Acid


  1. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Hoff, P.M., Saad, E.D., Ajani, J.A., Lassere, Y., Wenske, C., Medgyesy, D., Dwivedy, S., Russo, M., Pazdur, R. Clin. Cancer Res. (2003) [Pubmed]
  2. Oxonate-induced hyperuricemia and orotic aciduria in mice. Mangoff, S.C., Milner, J.A. Proc. Soc. Exp. Biol. Med. (1978) [Pubmed]
  3. Adjuvant polyarthritis. VI. Effect of oxonate-induced hyperuricemia on the development of acute inflammation, immune response and adjuvant arthritis. Chang, Y.H., Bluestone, R. J. Pharmacol. Exp. Ther. (1981) [Pubmed]
  4. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Nakamura, K., Yamaguchi, T., Ishihara, T., Sudo, K., Kato, H., Saisho, H. Br. J. Cancer (2006) [Pubmed]
  5. Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma. Konno, H., Tanaka, T., Baba, M., Kanai, T., Matsumoto, K., Kamiya, K., Nakamura, S. Jpn. J. Cancer Res. (1999) [Pubmed]
  6. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. van Groeningen, C.J., Peters, G.J., Schornagel, J.H., Gall, H., Noordhuis, P., de Vries, M.J., Turner, S.L., Swart, M.S., Pinedo, H.M., Hanauske, A.R., Giaccone, G. J. Clin. Oncol. (2000) [Pubmed]
  7. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. Cao, S., Lu, K., Tóth, K., Slocum, H.K., Shirasaka, T., Rustum, Y.M. Clin. Cancer Res. (1999) [Pubmed]
  8. Platelet aggregation in rats in relation to hyperuricaemia induced by dietary single-cell protein and to protein deficiency. Winocour, P.D., Turner, M.R., Taylor, T.G., Munday, K.A. Thromb. Haemost. (1978) [Pubmed]
  9. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis. Tominaga, K., Higuchi, K., Okazaki, H., Suto, R., Hamaguchi, M., Tanigawa, T., Sasaki, E., Shiba, M., Watanabe, T., Fujiwara, Y., Oshitani, N., Matsumoto, T., Arakawa, T. Oncology (2004) [Pubmed]
  10. Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats. Yoshisue, K., Nagayama, S., Shindo, T., Kawaguchi, Y. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
  11. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Osada, Y., Tsuchimoto, M., Fukushima, H., Takahashi, K., Kondo, S., Hasegawa, M., Komoriya, K. Eur. J. Pharmacol. (1993) [Pubmed]
  12. Aesculin possesses potent hypouricemic action in rodents but is devoid of xanthine oxidase/dehydrogenase inhibitory activity. Kong, L., Zhou, J., Wen, Y., Li, J., Cheng, C.H. Planta Med. (2002) [Pubmed]
  13. Decreasing effect of allantoxanamide, a hyperuricemic agent on renal functions in rats. Yonetani, Y., Iwaki, K., Ogawa, Y. Jpn. J. Pharmacol. (1987) [Pubmed]
  14. Hyperuricemia induced by the uricosuric drug probenecid in rats. Shinosaki, T., Yonetani, Y. Jpn. J. Pharmacol. (1991) [Pubmed]
  15. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats. Yoshisue, K., Masuda, H., Matsushima, E., Ikeda, K., Nagayama, S., Kawaguchi, Y. Drug Metab. Dispos. (2000) [Pubmed]
  16. Oxonic acid and fetal development: II.Teratogenicity in rats. Gralla, E.J. Toxicology (1976) [Pubmed]
  17. Effect of isoproterenol on renal uric acid excretion in rats. Sugino, H., Shimada, H. Jpn. J. Pharmacol. (1987) [Pubmed]
  18. Increased intestinal permeability correlates with gastrointestinal toxicity among formulations of the fluorouracil analogue tegafur in rats. Korenaga, D., Honda, M., Yasuda, M., Inutsuka, S., Nozoe, T., Tashiro, H. European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes. (2002) [Pubmed]
  19. Antihyperuricemic Lignans from the Leaves of Phyllanthus niruri. Murugaiyah, V., Chan, K.L. Planta Med. (2006) [Pubmed]
  20. DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer. Yoshida, K., Hamai, Y., Suzuki, T., Sanada, Y., Oue, N., Yasui, W. Anticancer Res. (2006) [Pubmed]
  21. Urate oxidase from the rust Puccinia recondita is a heterotetramer with two different-sized monomers. Aguilar, M., Montalbini, P., Pineda, M. Curr. Microbiol. (2002) [Pubmed]
  22. Intravenous infusion of diltiazem causes uricosuria with concomitant hypouricemia in rats. Sugino, H., Shimada, H. Biol. Pharm. Bull. (1996) [Pubmed]
  23. Platelet aggregation in rats made hyperuricaemic with nucleic adid-rich diets containing oxonate, and inhibitor of uricase [proceedings]. Winocour, P.D., Munday, K.A., Taylor, T.G., Tuner, M.R. The Proceedings of the Nutrition Society. (1976) [Pubmed]
  24. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats. Yoshisue, K., Hironaga, K., Yamaguchi, S., Yamamoto, A., Nagayama, S., Kawaguchi, Y. Cancer Chemother. Pharmacol. (2000) [Pubmed]
  25. Oxonic acid and fetal development: I. Embryotoxicity in mice. Gralla, E.J., Crelin, E.S. Toxicology (1976) [Pubmed]
  26. Effects of cassia oil on serum and hepatic uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver. Zhao, X., Zhu, J.X., Mo, S.F., Pan, Y., Kong, L.D. Journal of ethnopharmacology. (2006) [Pubmed]
  27. Hyperuricemic effects of cholinergic agents in rats. Iwaki, K., Yonetani, Y. Jpn. J. Pharmacol. (1982) [Pubmed]
  28. Use of the uricase-inhibited rat as an animal model in toxicology. Stavric, B., Nera, E.A. Clin. Toxicol. (1978) [Pubmed]
  29. Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. Matsushima, E., Yoshida, K., Kitamura, R., Yoshida, K. J. Chromatogr. B Biomed. Sci. Appl. (1997) [Pubmed]
WikiGenes - Universities